Response to Campbell et al.’s comments on our study “Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study”

We thank Campbell et al. for their relevant comments1 on our study “Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study”.2 They mention the low utilization of allogeneic hematopoietic stem cell transplantation (HSCT) in our study compared to the study by Campbell et al.3 The details on the recruitment of the 339 patients in our study and of patients who received allogeneic HSCT are provided in Table 1 below. Seventeen patients (5%) received allogeneic HSCT in our study: 7 patients from Saint-Louis Hospital (Paris), 2 from Clermont-Ferrand, 2 from Lille, 2 from Rennes, and 4 patients from Bordeaux, Montpellier, Cochin Hospital (Paris), Henri-Mondor Hospital (Créteil).